title: Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients.
abstract: Mean ratings of positive and negative symptoms and depression significantly improved in nine treatment-resistant schizophrenic patients who completed a 6-week open trial of fluoxetine added to their neuroleptics. The authors identify differences between responders and nonresponders and recommend controlled trials.
authors.affiliation: Erich Lindemann Mental Health Center, Massachusetts General Hospital, Boston.
authors.forename: D C
authors.initials: DC
authors.lastname: Goff
authors.forename: A W
authors.initials: AW
authors.lastname: Brotman
authors.forename: M
authors.initials: M
authors.lastname: Waites
authors.forename: S
authors.initials: S
authors.lastname: McCormick
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010865:Pilot Projects; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D005473:Fluoxetine